

CERTIFICATION OF TRANSLATION

Client: Heller, Ehrman, White & McAuliffe LLP 4250 Executive Square, 7th Floor La Jolla, CA 92037-9103

Date: December 1, 2000

Document Name:

Japanese Patent:

(11) Kokai (Unexamined Patent) Number: 57-185220

ANTI-CANCER DRUG HAVING CHLOROPHYLL DERIVATIVE EFFECTIVE COMPONENT

Corporate Translations Inc., hereby certifies that to the best of our knowledge and belief, has made an accurate and complete translation from <u>Japanese</u> to <u>English</u> of the original patent referenced above. The project has been adeptly managed through the three-phase quality process by three different experts: the translator, editor and proofreader. The translation team was specifically selected for their expertise in <u>Medical/Research/Japanese/Patents</u> to insure an accurate translation.

All necessary information including qualifications and expertise for the translation teams is on file at Corporate Translations Inc.

Lori Anding

Production Manager

info@corporatetranslations.com

1300 Aviation Blvd. Redondo Beach, California 90278 4011 🕿 310 376 1304 🗊 310 376 1394

(19) JAPANESE PATENT OFFICE (JP)

(12) PUBLICATION OF UNEXAMINED (KOKAI) PATENT APPLICATION (A)

(11) Kokai (Unexamined Patent) Number: 57-185220

(43) Date of Disclosure: November 15, 1982

A 6	Int. Cl. ³ Identif. Symbol Intra-Office Number ADU 6408-4C 7 D 487/22 8115-4C Number of Inventions: 1 Examination Requested: Not Yet Requested (Total of 7 Pages)
(54)	ANTI-CANCER DRUG HAVING CHLOROPHYLL DERIVATIVE EFFECTIVE COMPONENT
(21) (22)	Application Number: Sho 56-67593 Application Date: May 7, 1981
(72)	Inventor: Hiroshi Endo Hachoji-shi, Katagura-cho, 937-76
(72)	Inventor: Minoru Ichioka Hachoji-shi, Mibunocho, 86-17
(72)	Inventor: Hideo Hosoya Hino-shi, Hakusa 896-5
(72)	Inventor: Ryuko Koyama Kawasaki-shi, Tama-ku, Noboruko 1734
(71)	Applicant: Yakult Honsha Co., Ltd. Tokyo-to, Minato-ku, Higashi Shinbashi, 1-chome, 1-ban, 19-go
(74)	Representative: Takeo Minami, patent attorney
Specifi	cations
1.	Title of the Invention: Anticancer Drug Having Chlorophyll Derivative Effective Component

2. Scope of the Patent=s Claims

An anticancer drug having as an effective component a chlorophyll derivative, disclosed by the general formula:

general formula

[insert formula]

(in this formula, X indicates an H atom or OH base, Y indicates a -COOCH₃ base or H atom, Z is a Mg atom or 2 H atoms (position 13, 14).

3. Detailed Explanation of the Invention

This invention relates to a novel type of an anticancer drug having as an effective component a chlorophyll derivative.

More specifically, this invention relates to an anticancer drug having as an effective component a chlorophyll derivative, disclosed by the general formula:

general formula

[insert formula]

(in this formula, X is an H atom or OH base, Y indicates a COOCH₃ base or H atom, Z is a Mg atom or 2 H atoms (position 13, 14).

Chlorophyll derivatives expressed by the formula above have not been known at all from prior art.

[page 2]

The inventors of this invention have already discovered 10-hydroxy phaeophorbide (hereinafter referred to as OH-Phd) which displays an extremely powerful optical activity, developed from Chlorella cells treated according to a specific treatment (Nichidoka, Summary of Lectures from the 55^{th} Conference, see pages 476, 477). Next, when they were developing the physiological effect of the product, at the point when a chlorophyll derivative disclosed by the formula above was added, the inventors discovered that this not only caused selective cumulation in tumor cells via normal cells, but also that the discharge from the tumor cells was slow, and that the growth of tumors was suppressed. This was observed by the authors during irradiation conducted with visible rays in the range of $400 \sim 700$ nm. The authors also discovered that tumor

cells were destroyed, that discharge from normal organs and cells occurred quickly, that absolutely no reaction occurred in a dark environment and there was no toxicity.

The present invention is based on this discovery.

The following compounds can be used for the chlorophyll derivative expressed by the formula above.

Name		nbols in the Fo	2) Abbreviation	
	X	Y	Z	
10-hydroxyphaeophorbide <u>a</u>	-OH	-COOCH ₃	2H	OH-Phd
phaeophorbide <u>a</u>	-H	-COOCH ₃	2H	Phd
pyrophaeophorbide <u>a</u>	-Н	-H ·	2H	Pyrophd
10-hydroxychlorophyllide <u>a</u>	-OH	-COOCH ₃	Mg	OH-Chld
chlorophyllide <u>a</u>	-Н	-СООСН3	Mg	Chld
pyrochlorophyllide <u>a</u>	-Н	-H	Mg	Pyrochld

Notes:

1) X indicates position 10, Y indicates position 11 in the orientation of each substance.

-2H of Z indicates position 13 and position 14 in the orientation, Mg is linked to each N.

2. Materials Used in the Specifications

In recent years, it was disclosed (by T.J. Dougherty et al., in Cancer Research, <u>38</u>, 2628 \sim 2635, 1978) that the optical effect of hematoporphyrin derivatives was tested for the purposes of treatment of tumors. With respect to said phaeophorbides, it was discovered that OH-Phd is characterized by a relatively high optical activity when compared to hematoporphyrin, as well as by a high selective cumulation in tumors and a quick discharge from normal organ cells.

This substance is activated in particular in the optical wavelength band in the range of $400 \sim 700$ nm, it has a high transmissivity in living organism in the wavelength band range of $600 \sim 700$ nm (the effective wavelength region is $640 \sim 690$ nm), and the optical activity of this substance (activity per unit of time, per irradiating energy, and the dissolving amount of biological components per unit of administration) is as much as 10 times higher than that of hematoporphyrin (effective wavelength is 630 nm).

Phaeophorbides are non-toxic in living organisms in a dark environment, and even with visible light rays in the range of $400 \sim 700$ nm, if the light rays per se are not toxic.

Accordingly, this makes it possible to destroy tumor cells very effectively and also very safely through irradiation after controlled administration.

Glass fibers developed in recent years made it possible to perform irradiation with light rays in the internal parts of bodily organs. In addition, it was also confirmed that infrared light in the wavelength range of $600 \sim 700$ nm can be used for effective transmission of energy inside living organism up to about 3 cm. This means that basically all regions in tumors can be reached with irradiating light rays.

Furthermore, because very narrow directivity can be achieved by using laser light rays which have excellent condensing characteristics, this makes it possible to increase the effect of the reaction.

The optical effect is essentially caused by an excitation of a photosensitized substance contained in a living organism due to the energy of visible light rays. Subsequently, a safe oxygen activation occurs when active oxygen is generated (a certain type of oxygen, $^{1}O_{2}$). This is followed by oxidation and decomposition of lipids present in a living organism, as well as of protein nucleic acids, etc. Because the resulting effect is destruction to cells, this can cause indiscriminate damage to cells when a living organism that includes a photosensitized substance is irradiated by light rays. However, as long as this photosensitized substance is cumulated selectively in tumor cells, the tumor cells can be destroyed without exerting an influence on normal cells.

The following is a detailed explanation of this invention.

The method that was used to manufacture chlorophyll derivatives utilized for the anticancer drug of this invention will be explained first.

Said chlorophyll derivative manufacturing method is characterized by the fact that chlorophyllase contained in cells of green plants containing chlorophyll is utilized, as well as oxidation with dephytylization achieved by oxidation oxygen.

[page 3]

This method is thus a chemical manufacturing method using plants as inactivated raw material together with oxidation oxygen and chlorophyllase in cells or with isolated chlorophyll.

Among the raw materials that can be used with a method characterized by conducting oxidation and dephytylization with oxidation oxygen via chlorophyllase in cells of plants or chlorophyll in green plants are plants containing chlorophyll and having chlorophyllase activity and oxidation oxygen activity. Although any such plants can be utilized, it is best to use plants characterized by a large content of chlorophyll and a high level of oxygen activity for the purposes of mass production on an industrial scale. For instance Chlorella, Senedesmas, and similar green algae can be used as raw material from the viewpoint of the yield, the economic characteristics, etc.

The following is a detailed explanation of a concrete example of a method to manufacture said chlorophyll derivative by using Chlorella as the raw material.

After 10-hydroxychlorophyllide <u>a</u> was derived with oxidation oxygen from Chlorella cells containing chlorophyll a, Chlorella cells were cultivated again with a common method using derivation of 10-hydroxychlorophyllide via chlorophyllase inside the cells and by removing the carbon source, or in a buffer solution such as a phosphate buffer solution (pH 7.0), preferably at a temperature that is 5EC higher than a suitable temperature for Chlorella cells (about 40EC). The processing was conducted for a period of $6 \sim 48$ hours while the culture was stirred with an air current. (Treatment Solution - A).

After an organic solvent was then added to the treatment Solution - A obtained in this manner, for example acetone, methanol, ethanol (with a concentration of up to 70%, although an optimal concentration is 30%), the solution was aged for a period of 3 hours, preferably when the optimal temperature was reached (36EC), at a temperature conducive to the chlorophyllase effect in chlorophyll. (Aged Solution - B).

These operations were used to form an oxidized OH base containing hydrogen in position 10 in chlorophyll. After the phytyl base was substituted by H from position 12 in the chlorophyllase, this made it possible to obtain chlorophyllide a with phytyl in position 12 forming H without oxidation of 10-hydroxychlorophyllide <u>a</u> and position 10 in chlorophyll.

Chlorophyll pigment extraction can be used with generated OH-Chld and Chld according to a common method and a common refining method can then be used for isolation. For example, after centrifugal separation is applied to Aged Solution B, the supernatant is formed, methanol is then added again to the residue and the pigment is extracted. The supernatant is mixed with the extract and after the mixed solution is enriched under reduced pressure, chloroform is added and mixing is applied again. After that, distilled water is added which is followed by washing. The chloroform layer is removed so that a residue dissolved in ethanol can be obtained after chloroform is removed under reduced pressure. Then, separation can be conducted with thin layer chromatography, etc., and through distribution using a 17% hydrochloric acid solution, which makes it possible to obtain OH-Chld and Chld.

In addition, while the above described OH-Chld and Chld manufacturing method was used to obtain Treatment Solution - A used for Chlorella processing, and Aged Solution - B was obtained after that, a heat treatment was applied for 30 minutes at 70EC ($50 \sim 80EC$) to cells produced by Chlorella without preparing Treatment Solution - 1. Also, after suspension in acetone or another polar solvent with the above mentioned concentration, the product is allowed to age for 30 minutes to 3 hours at a temperature of $20 \sim 50$ EC in a neutral pH and the phytyl base in position 12 in chlorophyll is substituted by H from chlorophyllase, which makes it possible to obtain an optimal yield of chlorophyllide <u>a</u>. In addition, stirring can be applied with air current treatment for a period of about $8 \sim 24$ hours at a temperature of $20 \sim 50$ EC in a neutral pH in the acetone suspension solution with live Chlorella cells at the point when an optimal OH-Chld yield was obtained. Although the method to manufacture 10hydroxychlorophyllide <u>a</u> or phaeophorbide <u>a</u> utilized OH-Chld or Chld as the raw material during the above described manufacturing process, it is also possible to obtain the same result with a method replacing a Mg atom in porphyrine ring with a hydrogen atom according to a commonly used method, for instance with hydrochloric acid processing.

Mg can be easily substituted with a H atom with the hydrochloric acid solution with common processing involving separation and refining of OH-Chld or Chld, making it possible to obtain OH-Phd or Phd.

[page 4]

The OH-Phd or Phd obtained according to this invention can be mixed together or each item can be used as is. It is also possible to conduct separation and refining with thin film chromatography, etc. Pyrophaeophorbide <u>a</u> can be manufactured according to the method described by P.C. Pennigton et al [J. Am. Chem. Soc., 86, 1418, (1964)].

Pyrophd can be obtained for instance by treating chlorophyll a with pyridine and treating the pyrochloropyll obtained in this manner with hydrochloric acid, removing phytyl base in position 12 and replacing it with a hydrogen atom and creating a hydrogen atom from a Mg atom in porphyrine ring. In case of a chemical manufacturing method using as raw material chlorophyl that was already isolated from a plant or that does not have oxidation oxygen characteristics or chlorophyllase activity in the cells, the target compound can be obtained with the same manufacturing method also when the plant displays oxidation oxygen activity and chlorophyllase activity is used as described above, with the exception of chemical oxidation and dephytylization,

In this case, after the derivation of the hydroxychlorophyll obtained from chlorophyll by a weak oxidation, OH-Chld can be separated with saccharose column chromatography and after that, dephthylization is applied through a treatment using 30% hydrochloric acid, enabling to obtain OH-Phd with a high yield.

The inventors of this invention were thus able to obtain highly active OH-Phd and OH-

Phd characterized by a low activity. The data obtained is shown below in Table 1.

lable I

	High-Activity OH-Phd	Low-Activity OH-Phd
Molecular Formula	C35H36O6N4	C35H36O6N4
E ₆₆₇ /E ₄₀₉	1.93	1.99
R _f (TLC)	0.34	0.21
Chemical Shift	8 4.73	4.45
(NMR)	7 4.47	4.09

Notes:

 E_{667}/E_{409} : The ratio between the maximum absorption of red color and the maximum absorption of blue color in absorption spectrum of visible parts.

 R_f (TLC): The R_f value obtained with a thin silica gel layer, 20 x 20 cm, 0.25 mm, development solvent, benzene, ethyl acetone, ethanol, n-propanol (14 : 4 : 1).

Chemical Shift 8 and 7:

The chemical shift in the proton in position 7 and 8 obtained with nuclear magnetic resonance.

As one can see from Table 1, the high-activity OH-Phd and low-activity OH-Phd can be considered an optical isomer configuration in hydrogen position 7, 8 with high-activity OH-Phd and low-activity OH-Phd.

The effective amount for administration of the chlorophyll derivative in the anticancer drug of this invention is in each case in the range of 10 mg \sim 300 mg per daily dose for an adult, while the range of 50 \sim 150 mg is preferred.

With respect to the formulation of the anticancer drug of this invention, the preparation can be administered orally or as a preparation that can be injected according to a customary method. If the preparation is injected, it can be used after it has been dissolved in distilled water because Phd and OH-Phd can be dissolved directly in a symbiotic physiological salt solution. In addition, Phd can also be neutralized after it has been first dissolved in a weak alkaline solution and then it can be mixed with a physiological salt solution.

Furthermore, it should be added that the anti-cancerous effect of the above-described substance is not limited only to the above described example of this invention or to a manufacturing example of the anti-cancer drug of this invention or a drug example which was tested for toxicity.

Embodiment 1

 1.25×10^6 items of sarcoma 180 tumor cells were administered by subcutaneous inoculation to ICR mice (male mice, 7 weeks old, weighing about 25 g) per 1 mouse, and standard rearing was conducted after the grafting. The grafted group of individual mice in which growth of tumor cells was confirmed (10 mice in 1 group) was injected from the 8th day after the grafting with 0, 10, or 20 mg of OH-Phd per kilogram of body weight of the mice, dissolved in physiological salt solution, or with 20 mg/kg of Phd, Pyrophd, OH-Chld, Chld, or Pyrochld per kilogram of body weight of the mice, administered directly into the tumor region in the mice. This administration was conducted 9 times during a period of 3 days. Immediately after that, irradiation was conducted for 1 day, and for 6 hours, with rays in the wavelength range of 400 ~ 1,000 nm having a strength of 100 mW/cm² (with the light of a 500 W Tungsten lamp transmitted through 2 cm of a water layer providing a shielding profile for hot rays). The tumor was then extracted on the 32nd day after the grafting with the tumor took place, the weight of the tumor was measured and the tumor suppressing ratio was calculated based on the formula below.

suppression ratio % = average tumor weight in contrast segment - average tumor weight in tested segment x 100

The contrast group of the mice was administered a physiological salt solution in the same manner as the tested segment and they were also irradiated in the tumor region. In addition, the mice were fed OH-Phd in a dark environment with 20 mg/kg of body weight, and also the contrast group was kept in a dark environment. The results are shown in Table 1.

[page 5]

Because Chld, OH-Chld, Pyrochld are unstable properties, a Mg atom can be easily released into a living organism or into the molecules used during extracting operations, causing changes in Phd, OH-Phd, and Pyrophd.

The anti-tumor activity of these substances, corresponding to Mg-Phd, is almost identical.

	Administration Amount (mg/kg)	Light	Average Tumor Weight (g)	Suppression Ratio (%)
Contrast Segment	0	L	1.49 ∀ 1.46	0
OH-phd	90 180 180 180	L L L D	0.35 ∀ 0.41 0.19 ∀ 0.14 0.75 ∀ 1.04 1.43 ∀ 0.86	76.5 87.2 49.7 4.0
OH-Chld	180	·L	0.23 ∀ 0.38	84.6
Phd	180	L	0.63 ∀ 0.32	57.7
Chld	180	L	0.54 ∀ 0.47	63.8
Pyrophd	180	L	0.86 ∀ 0.72	42.3
Pyrochld	180	L	0.57 ∀ 0.42	61.7

Table 1 - Result of the anti-tumor effect after direct administration into the tumor of the chlorophyll derivative.

Notes:

L: Light rays with 20 Klux L^{*}: Light rays with 0.5 Klux

D: Dark environment.

Embodiment 2

Similarly to Embodiment 1, sarcoma 180 tumor cells were administered by subcutaneous inoculation into the dorsal region of ICR mice per 1 mouse and standard rearing was conducted after grafting. The grafted group of individual mice in which growth of tumor cells was confirmed was injected from the 8th day after the grafting with 0 mg, 0.3 mg, 1 mg, and 3 mg of OH-Phd and Phd per kilogram of body weight of the mice, dissolved in physiological salt solution, administered through the tail vein of the mice, resulting in a total of 11 administrations during an interval of $2 \sim 3$ days. Similarly to Embodiment 1, irradiation with light rays was conducted and after a period of rearing lasting 32 days, the tumor was extracted and the tumor suppression ratio was determined.

	Total Administered Amount - mg/kg of Weight	Light Rays	Average Tumor Weight (g)	Suppression Ratio (%)
Contrast Group Segment	0	L	5.54 ∀ 1.04	0
Admin. Segment OH-Phd	3.3 11 33 33 33	L L L L D	$1.05 \forall 0.6 \\ 0.68 \forall 0.60 \\ 0.18 \forall 0.18 \\ 2.36 \forall 1.44 \\ 4.43 \forall 0.87$	81.0 87.7 96.8 57.4 20.0
Admin. Segment Phd	3.3 11 33	L L L	$ \begin{array}{c} 1.6 \lor 0.87 \\ 1.3 \lor 1.44 \\ 2.3 \lor 1.29 \end{array} $	71.1 76.3 57.9

Table 2 - Anti-Tumor Effect with Administration of OH-Phd into tail vein

Notes:

L: 20 Klux

L^{*}: 0.5 Klux.

D: Dark environment.

An excellent effect was displayed with a joint administration of OH-Phd, Phd into the tail vein. The tumor was dissipated in about half of the mice in the group to which 33 mg of OH-Phd was administered.

Embodiment 3

Sarcoma 180 tumor cells were administered by subcutaneous inoculation into the dorsal region of ICR mice and after 23 days of standard rearing, when the grafted tumor grew to an approximate size range of $200 \sim 300 \text{ mm}^2$, 3 mg/kg of the body weight of the mice was administered through the tail vein. After 24 hours, irradiation was applied with light having an optical strength of 300 mw/cm^2 with shielded hot rays (using a 500 W light source, a Tungsten lamp) for 30 minutes to the tumor region. The administration of OH-Phd and treatment with irradiating light rays was repeated 3 times in daily intervals. After that, rearing was continued in a dark environment and the changes in the size of the tumor were observed. The segment which was not administered OH-Phd was given the same amount of physiological salt solution, while the light irradiation treatment was applied to this segment in the same manner.

	Total OH-Phd Admin. Amount (mg/kg of weight)	Size of Tumor during Administration (mm ²)	Tumor Size after 10 Days of Treatment (mm ²)	Suppression Ratio %
Contrast Segment	0	273 ∀ 6,4	376 ∀ 123	0
Tested Segment	. 9	248 ∀ 82	129 ∀ 79	66.0

Table 3 - Tumor treatment effect of OH-Phd

Note:

The size of the tumor (mm^2) ; long diameter x short diameter; after OH-Phd was administered. Because degenerative destruction occurred in the segment to which irradiation with light rays was applied, after 10 days, the size of the tumor has shrunk to about 1/3 (cubical conversion).

Embodiment 4

Similarly to Embodiment 1, sarcoma 180 was grafted to ICR mice and from the 8th day after the grafting, 0.10 mg OH-Phd was administered per kg of body weight of the mice orally by using a stomach probe. After the administration, the tumor region was irradiated with light rays for 30 minutes in 24 hour intervals in the same manner as in Embodiment 3 by using light rays with 300 mW/cm². The administration and treatment with irradiating light rays was conducted twice during a continuous period of 5 days for a total of 10 administrations. After rearing was conducted for 32 days, the tumor was extracted, its weight was measured and the suppression ratio was calculated.

Table 4 - Anti-Tumor effect with oral administration of OH-Phd

	Total Administered Amount (mg/kg)	Average Tumor Weight (g)	Suppression Ratio (%)
Contrast Segment	0	2.6 ∀ 1.5	0.
OH-Phd Segment	100	0.9 ∀ 0.5	65.4

Embodiment 5 (Toxicity Test)

[page 6]

[part of the top line illegible]

... ICR mice (male and female) whose weight was around 50 [illegible] g were used to conduct acute toxicity tests for each administration path.

For oral administration, the substance was administered with a stomach probe after it was dissolved in distilled water. For intravenous administration and administration into the abdominal cavity, the substance was dissolved in a physiological salt solution and then injected with a syringe. LD_{50} was calculated according to the Richfield-Wilcoxon method. Rearing was conducted after the administration in each case in a dark environment.

Administration Method	OH-Phd	Phd	Pyrophd
Intravenous Administration	200 <	200 <	200 <
Administration Into Abdominal Cavity	200 <	200 <	200 <
Oral Administration	1000 <	1000 <	1000 <

Table 5 - Acute toxicity characteristics in a dark environment (LD₅₀) mg/kg

The numbers shown in the figure indicate the limit for solubility of the administered substance in water or in a physiological salt solution. Death did not occur in either case.

Although absorption and discharge of the substance into normal cells and into organs, as well as hypersensitivity to light rays, was displayed with irradiation with light rays within 12 hours after the administration, no reaction was indicated with irradiation 24 hours after the administration. The administered substance was not observed in any cells or organs 24 hours after the administration.

Manufacturing Example 1

After Chlorella cells (1 kg of moist substance) were suspended in 5 l of a phosphate buffer solution (0.1 M, pH 7.0) and stirring was conducted for a treatment period of 48 hours with an air current at 40EC, the Chlorella cells were gathered by centrifugal separation and these cells were then dissolved in 3 l of a 30% acetone solution and then allowed to age for 3 hours at 36EC.

After the aging, centrifugal separation was conducted, the supernatant was extracted and the extract solution was obtained after 3 l of methanol were added 3 times to the residue.

The supernatant obtained in this manner mixed with the methanol extract solution was

then enriched under reduced pressure to 2 of the amount and after 2 l of chloroform were added to the resulting mixture, vigorous mixing was applied. Distilled water was added after that and washing was conducted, which was followed by separation conducted with a chloroform layer, making it possible to obtain a residue when the chloroform was removed under reduced pressure. The residue obtained in this manner was dissolved in 1 l of ethyl ether, and after an equivalent amount of 17% HCl solution was added, separation was conducted with a layer of hydrochloric acid solution. After the concentration of the hydrochloric acid was diluted to 5% with water, ethylene ether was added and the solution was mixed.

After this ether layer was separated and washing with pure water was conducted, the resulting mixture was enriched under reduced pressure. This enriched solution was applied to a silica gel layer and the coloring band ($R_f 0.39$ and $R_f 0.34$) was developed with a solvent (benzene, ethyl acetone, ethanol, n-propanol, 16 : 4 : 1 : 1) in a cool and a dark environment.

The coloring band obtained in this manner was then scraped off, methanol was added and the pigment was extracted, and after evaporation under reduced pressure in methanol, pigments (Phd 1.19 g, OH-Phd 0.86 g) were obtained.

Manufacturing Example 2

Acetone with a concentration of 30% was added to an enriched solution of live Chlorella cells, and after strong ventilation was conducted with a pH of 7.0 and a temperature of 36EC for a period of 24 hours, the chlorophyll pigment was manufactured with extraction, separation, and refining according to the same manner as in Embodiment 1.

492 mg of Phd and 386 mg of OH-Phd were obtained from 100 g of Chlorella algae.

Manufacturing Example 3

After dried Chlorella powder (inactivated chlorophyllase) was pulverized with a homogenizer to obtain a fine powder, the powder was suspended in a 30% acetone solution, and after ventilation and stirring was conducted with an air current for a period of 24 hours, a chlorophyll-based pigment was obtained according to the same method that was used in Manufacturing Example 1. Next, a hydroxy chlorophyll fraction was separated with saccharose column chromatography (0.5% development solvent comprising isopropanol - petroleum ether), and after the solvent was distilled out, the resulting mixture was dissolved in ethanol ether. Next, an equivalent amount of 30% hydrochloric acid was added and after vibrations were applied in a a dark environment at room temperature for a period of 1 hour and after dephytylization was conducted, water was added, as well as a 17% hydrochloric acid concentration. Ether was then added to achieved pigment distribution, a 17% HCl fraction was formed and refining was conducted in the same manner as in the case of Manufacturing Example 1. This made it possible to obtain 618 mg of OH-Phd from 100 g of Chlorella algae.

Manufacturing Example 4

100 mg of chlorophyll <u>a</u> was dissolved in 50 ml of acetone and 60 g of silica gel (soda silicate) was added for adsorption of chlorophyll, and after acetone was evaporated, aging was conducted for 1 hour at 36EC in a dark environment with air current ventilation. After the adsorption, the adsorbed pigment was dissolved in acetone and enriched under reduced pressure at a low temperature in a dark environment.

[page 7]

After dissolution in ethylene ether, the hydroxy chlorophyll fraction was separated with saccharose column chromatography in the same manner as in Embodiment 3, the hydroxy chlorophyll fraction was scrapped off, dissolved in ether, an equivalent amount of a 30% HCl solution was added, and after dephytylization, water was added to create a 17% concentration of hydrochloric acid. This was followed by the same refining process that was also used in Manufacturing Example 1.

This made it possible to obtain 32 mg of OH-Phd from 100 mg of Chlorella.

Preparation Manufacturing Example 1

After 15 mg of OH-Phd was dissolved in 0.5 ml of sterilized distilled water and after dilution was conducted with 0.5 ml of 1.8% physiological salt solution, the mixture was filtered through a bacteria removing filter, poured into an ampule for sterile injection and stored in a dark environment.

Preparation Manufacturing Example 1

After 1,500 mg of a mixture consisting of 630 mg of OH-Phd and 870 mg of Phd was dissolved in 50 ml of 0.1 N NaOH, approximately 50 ml of 0.1 N HCl was added to achieve neutralization. In addition, the mixture was filtered through a bacteria removing filter, poured into an ampule for sterile injection, sealed and stored in a dark environment.

特開記57-185220(2)

1)

	⑲ 日本国特許月	F (JP)	
Q2	公開特許公		① 特 許 出 願 公 開
喇叭記号	庁内整理番号	THX (A)	昭57—185220
ADU	6408-4C	國公開	昭和57年(1982)11月15日
	8115—4 C	発明の 審査請	数 1

^秀導体を有効成分とする制ガン

40 22

藤寛

司稔

356-67593 @発 眀 56(1981)5月7日 @出 鯂 王子市片倉町937—76 E子市弐分方町86—17

(全7頁) ⑫発 明 者 細谷英雄 日野市百草896-5 者 小山隆子 川崎市多摩区登戶1734 人 株式会社ヤクルト本社 東京都港区東新橋1丁目1番19 创代理人 弁理士 南孝夫


紿 フイル誘導体を有効成分 制ガン剤

СН-`сн.

基であり、Yね -coocH3 İMB原子又は2ヶのH

>す)で示されるクロ とする制ガン剤。

導体を有効成分とす



(式中XはH原子叉はOH基であり、Yは-COOCH3 基又は日原子であり、 Z はMg原子又は 2 ヶの H 原子(13.14位)を表わす)で亦されるクロ ロフイル誘導体を有効成分とする制ガン剤に開 する。

上記式で表わされるクロロフィル誘導体が制 ガン剤として便用し得ることについては従来、 全く知られていない。

本発明者らは、先にクロロマイルを多量に含 むクロレラの特殊処理細胞から優めて強力を光 力学的活性を示す10-ハイドロオキシフェオ

1) 式中の記号 2)	٦
X Y Z B	
-OH -COOCH3 2H OH-Phid	
-H -COOCH3 2H Phd	
-H -H 2H Fyrophd	1
-OH -COOCH, Mg OH-Chid	
-H -COOCH3 Mg Chid	
-H -H Mg Pyrochid	
「は11位に各々配位する) e
~ 1 3 . 1 4 位 亿 配 位 、 Mg は	
É	
よいて便用	
ば (T.J.Dougherty et al.	
.2628-2635 1978) ~ - +	
を用いてそれらの光力学的	
の治療を試みている。上記	
ド類、就中OH-Phd はこのへ	
比較し光力学的活性が高く、	
住大きく、正常な胸袋和か	
性をもち、集光性のすぐれ	
いれば、より反応を高める	1
** ***	
本来、生体に取りこまれた	
; 線のエネルギーによつて励 ; な酸素をためルトーーに。	· . [
☆酸素を活性化して、活性 ○2)を生成し、これが生体	l .
∃質,核酸等の酸化分解し、細	
す作用であるので、光増感物	
本に光が照射されれば、無差	
生ずるのであるが、その光増	1
に選択的に蓄積する物質であ	
響を及ぼすことなしに肿瘍を	
が可能となる。	
さらに詳細に説明する。	
明の制ガン剤に用いるクロロ	
造方法について記す。	,
造方法について記す。 イル誘導体の製造方法には、	•

ロフイルを植物の籼桐内のク

及び酸化酵素で酵素的に脱っ

イチール化し、酸化することを特徴とする方法 とすてに単離されているクロロフイルあるいは 細胞内のクロロフイラーゼや酸化酵素の不活化 された植物を原料として化学的に製造する方法 とがある。

緑色植物中のクロロフイルを植物の細胞内の クロロフィラーゼ、及び酸化酵素で酵素的に脱 フィチール化及び酸化を行うことを特象とする 方法で用いる原料としては、クロロフイルを含 みかつクロロフイラーゼ活性及び酸化酵素活性 のある植物は、任意に利用することができるが、 クロロフイル含量が多く酵素活性が高く、かつ、 工業的に大量生産が可能である植物、例えばク ロレラ、セネデスムスの様な緑色酸細葉類等を 原料とするのが、収率、経済性等の点からみて 有利である。

以下、クロレラを原料とした場合の上記のク ロロフイル誘導体の製造法の具体例についてさ らに詳細に説明する。

クロレラ細胞中のクロロフイル&を細胞内蔵

12位のフィチール基がHとなつたクロロフィ ライドaを得ることができる。

生成した OH-Chid 及びChid は通常行なわれて いるクロロフイル類色素の抽出、精製方法に従い単離することができる。例えば、静置液-B を速心分離した後、上清をとり、残羞は更にメ タノールを加えて色素を抽出し、上清、抽出液 の混液を滅圧下濃縮後クロロホルムを加えて混 合した後、さらに蒸留水を加えて水洗を行ない その後クロロホルム層をとり滅圧下クロロホル ムを留去して得られる残渣をエーテルに溶解し た後、17%塩酸器液との液々分配更に薄層ク ロマトグラフィ等により分離することにより、 OH-Chid 及びChidを得ることができる。

また、前述の OH-Chid 及びChidの製造法において、クロレラを処理して処理液 - A とした後に静質液 - B を得たのであるが、処理液 - A とすることなしにクロレラ生細胞を70℃(50~80℃)30分加熱処理、又はアセトン等の 復性容媒に前記濃度に融濁し、pH 中性附近、温 特閒昭57-185220(3)

化酵素で10~ハイドロオキシクロロフィスa に誘導し更に細胞内クロロフィラーモにより10 ~ハイドロオキシクロロフィラーモにより10 目的でクロレラを培養する際に通常用いられて いる培地より炭素原を除いた培地、あるいはリ イ酸鉄衛被(pH 7.0)のような鉄衛剤中で好ま しくはクロレラ細胞の遅晶より約5 で高い温度 (約40℃)で、通気攪拌を行ないながら6~ 48時間処理する。(処理液 - A)

得られた処理液 - Aに水茶性の有機希線、 例 えばアセトン、メタノール、エタノール(70 % までの濃度、最速濃度30%)を加えてクロ ロフイル中のクロロフイラーゼの作用温度内、 好ましくは至遠温度(36℃)にておよそ3時間 静置する。(静置液 - B)

これらの換作によりクロロマイル中の10位 の水素が酸化されてOH基となり、クロロフイラ ーゼにより12位のフイチール基がHに催換さ れた10 - ハイドロオキシクロロフイライド<u>e</u> 及びクロロフイルの10位が酸化されておらす、

度20~50 てで30分ないし3時間静蔵すると とによりクロロフイル中の12位のフイチール 基をクロロフイラーゼによりHに貴歩させると とにより、クロロフイライド車をより良好な収 率で得ることができる。またOH-Chidを良好な 収率で得たい時にはクロレラ生細胞のアセトン 懸濁液をpH中性附近、 腐度 20~50 し、通気攪 件処理を約8~24時間行うことによつても得 られる。10- ハイドロオキシフェオフォルバ イド車あるいはフェオフオルバイド車の製造方 法は、上述のごとくして製造したOH-Chid ある いはChidを原料として、通常行をわれるボルフ イリン環のMg原子を水素原子に貴換する方法、 例えば塩酸で処理する方法に従い、それぞれ得 ることができる。

通常 OH-Chid あるいはChidを分離精製する工 程で用いる塩酸溶液により容易にMgが H 原子に 置換し、OH-Phd あるいは Phd として待られる。 本発明においては、上記で得られた OH-Chid と Chid、あるいはOH-Phd と Phd は夫々 化合物の まま使用するとともできるがこれらは必要に応 じ薄層クロマトグラフィー等で分離精製しても よい。ピロクロロフィライド a あるいは、ピロ フェオフオルバイド a は、 F.C.Pennington 6の 方法 (J.Am.Chem.Soc.86,1418(1964)) に従い、 製造することができる。

- .

例えば、 Fyrophd はクロロフイル a をビリジ ンで処理することにより得られるビロクロロフ イルを塩酸で処理して 1 2 位のフィチール基を 除いて水素原子とし、またポルフイリン環のMg 原子を水素原子にすることにより得ることがで きる。細胞内のクロロフイラーゼ活性や酸化酵 素活性のない植物あるいはすでに単離されてい るクロロフイルを原料として化学的に製造する 場合は、化学的に酸化及び脱フィチールするこ とを除けば、前述のクロロフィラーゼ及ひ酸化 酵素活性のある植物を原料とする場合の製造法 と同様の方法に従つて目的とする化合物を得る ことができる。

この場合おだやかな酸化によつてクロロフィ

表 - 1 から高活性OH-Phdと低活性OH-Phdは 7.8 位水素の立体配位の光学異性体と思われる。 本会明の制ガン剤における上記のクロロフ1 ル 療導体の有効投与量はそのいずれもおよそ成 人 1 日当り 1 0 号 ~ 3 0 C 号、好ましくは 5 0 ~ 1 5 0 号である。

本発明の制ガン剤の製剤化にあたつては経口 投与用製剤、あるいは注射用製剤のいずれても 通常行なわれる製剤化方法により製剤化が行わ れるが、注射用製剤とするにあたつては Phd、 OH-Phd共生理食塩水に直接溶解しにくいので、 蒸留水に溶解した後、生理食塩水と混合して便 用するのが良い。また、 Phd はあらかじめ弱ア ルカリ性溶液に溶解した後中和し、生理食塩水 と混和するのがよい。

次に上記物質の制ガン作用、毒性に関する乗 理学的実験例及び本発明の制ガン剤の製造例、 製剤化例をあげるが本発明はこれらの例示によ つて特定されるものではない。 特閒昭57-185220(4)

ルからハイドロオキシクロロフイルを許導した 後囲港カラムクロマトグラフィーによりOH-Otale を分離し、彼ろ0%塩酸処理により肥フィーー ルすると、効率よくOH-Phdのみが待られる。 本発明者らは、高活性のOH-Phdと低活性の OH-Phdについて、調べた結果、以下の表 - 1に 示す如きデータが得られた。

表 - 1

	高活性 OH-Phd	低活性 OH-Phd
分子式	C35H3606N4	C35H3606N4
E067/E409	1.93	1. 9 9
R _f (TLC)	0.34	0.21
ケミカルシフト (NMR)	8 4.73 7 4.47	4.45 4.09

迕	E667/F409	; 可視部吸収スペクトルにおける青色優 大吸収と赤色極大吸収の比
	R _f (TLC)	: シリカゲル浦廠、20×20m、0.25

ケミカルシフト B) 核磁気共鳴における 7 、 b 位プロト 7〕 ンのケミカルシフト

ザルコーマ180腫瘍細胞をICRマウス(単 7週令、約259)の背部皮下にマウス1匹当 91.25×10⁶個接種し、操準飼育し確実に特确 細胞の増殖を認めた個体(1群10匹)に移植 後8日目から生理食塩水に若かしたOH-Phdをマ ウス体重kg当90.10.20 mg又はPhd.Pyrophd. OH-Chid,Chid,Pyrochidを各々20mg/kg体重 をマウスの随傷部位に直接投与した。試験期間 中3日かきに9回の投与を行つた。直ちに放長 400~1000nmの強度100mW/tm2の光(500 Kタングステンランプの光を30mの水層を通し て熱粉遮断)を1日、6時間単射した。清濃釋 植後32日目に腫瘍を摘出し、その重量を測定 し次式によつて噎暢抑制架を算出した。

対照群マウスは生理的食塩水を試験区と同様、 腫瘍部位に投与し同様に光照射した。又OH-Phd 20町/kg体重投与群を暗所で飼育し、暗所 21 照群とした。結果は表1に示されている。

実験例 1

Chid,OH-Chid,Pyrochid は不安定な物質で生体中或いは抽出操作中分子中のMg原子が容易にはずれて、各々 Phd,OH-Phd,Pyrophd K変化する。 それらの抗肺瘍活性は各々対応する Mg - 欠 Phd 類のそれとほぼ同様であつた。

表1クロロフイル誘導体の腫瘍直接投与による抗腫瘍効果

	総投与量 ■9/kg	<u></u>	平均朣瘍 重 貴(9)	打佛)军 _(%)
対照区	0	L	1.49±1.46	0
OH-phd	90 180 180 180	L L L D	0.35±0.41 0.19±0.14 0.75±1.04 1.43±0.86	76.5 87.2 49.7 4.0
OH-Chld	180	L	023±038	84.6
Pnd	180	L	0.63±0.32	57.7
Chld	180	L	0.54±0.47	63.8
Pyropnd	180	L	0.86±0.72	42.3
Pyrochld	180	L	0.57±0.42	6 1.7
註 L;;	20 Klux			
L*;)	τ Ο. 5 Κι μ π			
D;#	2			

実験例 2

OH-Phd,Phd,共に静脈投与は敬量の投与で著効 を示した。 OH-Phd 33町投与照射群の中、約半 款のマウスの腫瘍は消失した。

実解例 3

ザルコーマ180を背部皮下に移植した ICR マウスを23日間標準飼育し移植腫瘍が約200 ~300mm²の大きさに増殖したマウスにOH-Phd 3 mg/kg体重を尾静脈より投与、24時間後に 熱線を遮断した光強度300mw/cm²の光(光源 500W、タングステンランプ)を30分間腫瘍 部位へ照射した。OH-Phd 投与、光照射処置は隔 日に3回行ない、その後暗所飼育を続け、腫瘍 の大きさの変化を観察した。OH-Phd 無投与区は 同量の生理食塩水を投与し、同様の光照射を行 つた。

表 3. OH-Phd の腫瘍治療効果

	OH-Phd 総投 与_(#g/kg体重)	<u> 投与時腫瘍の</u> 大きさ(mm ²)	処置 10日後の腫 瘍の大きさ(mm ²)	抑制率
対照区	0	273±64	376±123	0
試験区	9	248±82	129±79	66.0

持開昭57-185220(5)

実験例1と同様にICR マウス背部皮下に中心 コーマ180種場細胞を移植体、使産能育し、 確実に陣得細胞の増殖を認めた個体に移植を日 後から生理食塩水に好かしたOH-Phd 及び Fnd を マウス体重約当り0時、0.3時、1時、3時をマウス 尾静脈より投与、2~3日間隔で訂11回投与 し、実験例1と同様に光照射し32日間創作後、 陣傷を摘出、陣場抑制率を調べた。

表 2. OH - Phd の尾静脈投与による抗腫瘍効果

		総投与量 ■9/×9体重	· <u>光</u>	平均褲鴉 正信(9)	抑制速 (%)
対照区		0	L	5.54±1.04	0
投与区 OH-Phd	{	3.3 11 33 33 33 33	L L L D	1.05 ± 0.6 0.68 ± 0.60 0.18 ± 0.18 2.36 ± 1.44 4.43 ± 0.87	8 1.0 8 7.7 9 6.8 5 7.4 2 0.0
投 与 区 Phd	{	3.3 11 33	L L L	1.6+0.87 1.3+1.44 2.3±1.29	7 1 1 7 6.3 5 7.9
赶	L L D	*: 0.5 K			

実験例 4

実験例1と同様にザルコーマ180を ICR マ ウスに移植し、移植後8日目から水に影解した OH-Phd を 0,10 町/町体重、 目ゾンデを用いて 経口的にマウスに投与し、投与後、24時間後 30分間腫瘍部位に実験例3と同様300mW/cm² の光を照射した。投与および光照射処置は5日連 続2回計10回行つた。32日間飼育した後肺 傷を摘出し、その重點を評定して抑制率を算出 した。

表 4. OH-Phd の経口投与による抗静傷効果

	総投与景 (#9/kg)	平均胜势重都 (9)	抑 制 率; (70)
対 熈 区	0	2.6 ± 1.5	0
OH-Phd 🗵	1 0 0	0.9±0.5	6 5.4

実験例5(毒性試験)

特開昭57-185220(6)

体重309前後のICR マウス(雌、雄)を用いて、各投与経路による急性毒性試験を行なつた。

経口投与は蒸留水に落解したものを胃ゾンデ を用いて投与し、静脈内投与、腹腔内投与は生 現食塩水に各々溶解し、注射器によつて行つた。 LD50はリッチマイールド・ウイルヨクソン法に より算出した。投与後いずれも暗所で飼育した。

表 5. 暗 所 に お け る 急 性 毒 性 (LD₅₀) #g / #g

<u> </u>	OH-Phd	Phd	Pyrophd
静脈内	200<	200<	200<
腹腔内	200<	200<	200<
経口	1000<	1000<	1000<

表中の数字は投与物質の水、生理食塩水への 群解度の限界を示すものであるが、いずれも死 亡しなかつた。

これらの物質の正常細胞、臓器への吸収排泄 は速やかで投与後12時間以内の光照射で光過 敏症を呈するが、投与24時間以後の照射では 何らの反応を示さなかつた。投与24時間後に

.

エチルエーテルを加えて混合する。このエーテ ル 府を分離し水で洗 伊した後、 滅圧下で 濃縮す る。この 濃縮液を シリカゲル 薄層に塗布して、 容媒 (ベンゼン、エチル アセテート、エタノー ル、 n - プロペノール、 16:4:1:1) で 府 暗 所にて 展開して 色素 バンド (Rf 0.39と Rf 0.34) を 得た。

得られた色柔バンドをかき取り、メタノール を加えて色素を抽出し、減圧下でメタノールを 解去し、色素(Phd 1.199、OH-Phd 0.869)を 得た。

製造例 2

クロレラ生細胞濃縮液にアセトンを30%濃度に加え、pH70温度36℃で散しく通気24時間後、製造例1に従いクロロフイル系色素を抽出分離精製した。

クロレラ染体 1009から Phd 4 9 2 mg、OH-Phd 3 8 6 町が得られた。 製造例 3

クロレラ乾燥粉末(クロロフイラーゼ不活性)

は各細胞、臓器に投与物質は殆ど説かられなか つた。

製造例 1

クロレラ細胞(虚体 1 kg)をリン酸料面液 (0.1 M、pH 7.0) 5 とに懸濁し、 4 0 てで通気 操件処理を 4 8 時間行なつた後、速心分離を行 ないこのクロレラ細胞を乗めて、これに 3 0 % の 7 モトン密液 3 とを加えて 3 6 てにて 3 時間 静置する。


静置後、遠心分離を行ない上南を採取し、更 に残僚に3とのメタノールを3回加えて抽出殺 を得た。

得られた上清とメタノール抽出液の武液を施 圧下に始着まで碘和し、これにクロロホルムを 2 4 加えて散しく混合後、蒸留水を加えて水洗 を行ない、この後クロロホルム層を分離して、 液圧下にクロロホルムを除去し残酷を得る。 得 られた残益をエチルエーテル14に容解し、等 置の17% HC4 溶液を加えた後、塩酸溶液層を 分離し、水で5%の塩酸酸度まで希釈した後、

をホモジナイザーで細胞破砕後30%アセトン 溶液に懸濁し、24時間通気攪拌後、製造例1 に従つてクロロマイル系色素を抽出し、次いで 蔗糖カラムクロマトグラフイー(展開新設0.5 %イソプロパノール・石油エーテル)でハイド ロオキシクロロフイル画分を分離し、耐線留去 後エチルエーテルに溶解し、等量の30%塩酸 を加え暗所下、窒温で1時間振盪して脱フイチ ール化を行つた後、水を加えて塩飽夢及を17 %とし、エーテルを加えて色素を分配、17% HCと画分をとり、以下製造例1と同様に精製し た。クロレラ融体1009からOH-Phd 618 町が 得られた。

製造例 4

精製したクロロフイル 4 100 町をアセトン に 密かし、シリカゲル(硅酸ソーダ) 609 を 加えてクロロフイルを吸着し、アセトンを揮発 させた後、暗所下空気中で 3 6 ℃に 1 時間 数置 する。後吸着した危景をアセトンで解出し、暗 所仮温下で滅圧感縮し、エチルエーテルに超い



し以下製造例3と同様にして無糖カラムクロマ トグラフィーにかけて、ハイドロオキシクロロ フィル画分をとり、エーテルに帯解し、等量の 30% BCL 溶液を加え、脱フィチール後、水を 加えて17% 塩酸濃度とし以下製造例1と同様 処理後常製した。

クロロフイル100町からOH-Phd 32町が得られた。

製剤化例 1

OH-Phd 1 5 号を被菌蒸留水 0.5 形に溶解した 役、 1.8% 食塩水 0.5 配で希釈後、除菌フイル ターで炉過して、無菌的に注射用アンプルに充 テンし、暗所に保存した。

製剂化例 2

OH-Phd 630 By、Phd 870Bの混合物1500 Byを 0.1 N NaOH 溶液 50mに溶解後 0.1 N HCと 密 液約 50mを加えて中和する。更に 2% 食塩水 を加えて 150mとする。 広いで除動フイルタ - で戸巡して、無菌的に注射用ナンプルに充て ん、 触閉し、暗所に保存した。